About the Company
Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenix Inc., the company went public in 1992. Initially focused on developing its own drugs, a period of turbulence in the early 2000s culminated in its CEO being ejected by the shareholders and provoked a change in focus to the acquisition of existing drugs and forming partnerships to develop them further. The company has been the subject of multiple regulatory investigations, negative shorts-seller reports and class action lawsuits amid allegations of securities fraud. In 2018 its CEO was listed among the top five highest paid CEOs in San Diego.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $LGND News
Ligand Beats Lawsuit Over 401(k) Payout to Worker’s Ex-Wife
Ligand Pharmaceuticals Inc. is free from a lawsuit by a former employee who said the company wrongly distributed his 401(k) account to his ex-wife and fired him when he challenged the move in court.
Ligand Enters Into $100 Mln Royalty Financing Agreement With Agenus For BOT/BAL Clinical Dvpt.
Ligand Pharmaceuticals Inc. (LGND) announced a royalty financing agreement with Agenus Inc. (AGEN) to support Agenus' key development ...
Ligand Pharmaceuticals Inc Q1 Profit Increases, beats estimates
Ligand Pharmaceuticals Inc (LGND) revealed a profit for its first quarter that increased from the same period last year and beat the ...
Ligand Pharmaceuticals Inc (LGND) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ...
Discover how Ligand Pharmaceuticals Inc (LGND) kicked off 2024 with strong financial results and strategic expansions, setting a positive tone for the year ahead.
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) and Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the ...
Ligand: Q1 Earnings Snapshot
JUPITER, Fla. (AP) — JUPITER, Fla. (AP) — Ligand Pharmaceuticals Inc. (LGND) on Tuesday reported net income of $86.1 million in its first quarter. The Jupiter, Florida-based company said it had net ...
Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B
Whether you're just getting started with investing or have some extra cash, these stocks are solid choices.
Ligand Pharmaceuticals Inc (LGND) Reports Mixed Q1 2024 Results: Misses Revenue Estimates but ...
Ligand Pharmaceuticals Inc ( NASDAQ:LGND) released its 8-K filing on May 7, 2024, detailing its financial results for the ...
Ligand Pharmaceuticals Inc LGND
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Ligand Enters Into $100 Mln Royalty Financing Agreement With Agenus For BOT/BAL Clinical Dvpt.
(RTTNews) - Ligand Pharmaceuticals Inc. (LGND) announced a royalty financing agreement with Agenus Inc. (AGEN) to support Agenus' key development initiatives in the ongoing botensilimab and ...
Ligand Pharmaceuticals Inc LGND
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...